Based in Chicago, Illinois, AveXis is a clinical-stage gene therapy company developing innovative treatments for rare and life-threatening genetic diseases.  Our gene therapy product candidate, scAAV9.CB.SMN (AVXS 101), is currently in a Phase 1 clinical trial in the United States for the treatment of spinal muscular atrophy (SMA) type 1.  SMA is the most common cause of genetic infant mortality and the second most common autosomal recessive disease.  No treatment is currently approved for the treatment of SMA in the United States, Europe or other geography.  The SMA program has received Orphan Drug designation in both the United States and Europe.
 
AveXis is a rapidly growing leader among gene therapy biotech companies and continues to establish relationships with academics, biotechnology and pharmaceutical companies, and healthcare investors.
Type
Private
HQ
Bannockburn, US
Employees
54 (est)
AveXis is headquartered in Bannockburn, US

AveXis Locations

Bannockburn, US

AveXis Metrics

AveXis Summary

Total Funding

$75 M

Latest funding size

$65 M

Time since last funding

about 1 year

Investors

AveXis's latest funding round of $65 M was in September 2015. In total, AveXis has raised $75 M.

AveXis Company Life

You may also be interested in